Truist Financial’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$144M Buy
941,818
+54,522
+6% +$8.36M 0.19% 103
2025
Q4
$122M Buy
887,296
+54,682
+7% +$7.16M 0.16% 123
2025
Q3
$107M Buy
832,614
+34,147
+4% +$4.17M 0.14% 144
2025
Q2
$96.6M Buy
798,467
+28,726
+4% +$3.24M 0.14% 144
2025
Q1
$85.8M Sell
769,741
-1,914
-0.2% -$204K 0.14% 153
2024
Q4
$75.1M Buy
771,655
+27,092
+4% +$2.89M 0.12% 166
2024
Q3
$85.6M Sell
744,563
-5,842
-0.8% -$663K 0.13% 147
2024
Q2
$79.9M Sell
750,405
-5,657
-0.7% -$568K 0.12% 171
2024
Q1
$73.1M Sell
756,062
-74,303
-9% -$7.62M 0.11% 178
2023
Q4
$83.8M Sell
830,365
-33,494
-4% -$3.23M 0.13% 151
2023
Q3
$88M Buy
863,859
+85,075
+11% +$8.64M 0.15% 147
2023
Q2
$78.6M Sell
778,784
-52,632
-6% -$5.26M 0.13% 157
2023
Q1
$76.5M Sell
831,416
-124,363
-13% -$10.9M 0.13% 162
2022
Q4
$86.7M Sell
955,779
-10,416
-1% -$877K 0.15% 142
2022
Q3
$73.4M Sell
966,195
-8,089
-0.8% -$671K 0.14% 146
2022
Q2
$82.4M Sell
974,284
-120,349
-11% -$10.6M 0.15% 140
2022
Q1
$96.1M Buy
1,094,633
+76,233
+7% +$6.6M 0.15% 141
2021
Q4
$89.1M Sell
1,018,400
-16,861
-2% -$1.4M 0.14% 166
2021
Q3
$84.7M Buy
1,035,261
+35,423
+4% +$3.19M 0.14% 163
2021
Q2
$91.2M Buy
999,838
+31,103
+3% +$2.77M 0.15% 148
2021
Q1
$82.8M Buy
968,735
+76,499
+9% +$6.86M 0.14% 157
2020
Q4
$84.3M Buy
892,236
+54,765
+7% +$4.79M 0.16% 143
2020
Q3
$72.8M Buy
837,471
+6,719
+0.8% +$582K 0.16% 142
2020
Q2
$72.6M Buy
830,752
+27,160
+3% +$2.34M 0.16% 145
2020
Q1
$66.3M Buy
803,592
+52,164
+7% +$4.65M 0.17% 133
2019
Q4
$71.2M Buy
751,428
+604,435
+411% +$54.2M 0.14% 156
2019
Q3
$12.8M Sell
146,993
-3,816
-3% -$343K 0.22% 115
2019
Q2
$13.8M Sell
150,809
-25,167
-14% -$2.13M 0.24% 106
2019
Q1
$15.2M Sell
175,976
-13,058
-7% -$1.05M 0.27% 98
2018
Q4
$14.5M Sell
189,034
-6,231
-3% -$485K 0.3% 91
2018
Q3
$15.1M Sell
195,265
-2,563
-1% -$189K 0.27% 97
2018
Q2
$13.4M Sell
197,828
-32,699
-14% -$2.26M 0.25% 99
2018
Q1
$16.7M Sell
230,527
-37,119
-14% -$2.83M 0.32% 85
2017
Q4
$20.1M Sell
267,646
-80,092
-23% -$6.04M 0.38% 68
2017
Q3
$26.8M Sell
347,738
-10,442
-3% -$789K 0.52% 43
2017
Q2
$26.8M Sell
358,180
-6,319
-2% -$448K 0.53% 43
2017
Q1
$24.3M Buy
364,499
+27,845
+8% +$1.86M 0.49% 45
2016
Q4
$22M Buy
336,654
+9,327
+3% +$605K 0.45% 51
2016
Q3
$23.2M Buy
327,327
+3,074
+0.9% +$224K 0.48% 49
2016
Q2
$24M Buy
324,253
+10,740
+3% +$742K 0.5% 44
2016
Q1
$20.4M Buy
313,513
+16,763
+6% +$1.14M 0.53% 43
2015
Q4
$22.9M Sell
296,750
-13,912
-4% -$1.11M 0.59% 37
2015
Q3
$25.6M Sell
310,662
-11,667
-4% -$1.04M 0.67% 33
2015
Q2
$28.4M Sell
322,329
-17,423
-5% -$1.6M 0.77% 25
2015
Q1
$30M Sell
339,752
-40,634
-11% -$3.6M 0.86% 19
2014
Q4
$31.6M Sell
380,386
-5,559
-1% -$461K 0.93% 17
2014
Q3
$32.6M Sell
385,945
-13,580
-3% -$1.1M 0.98% 15
2014
Q2
$32.4M Sell
399,525
-14,290
-3% -$1.12M 0.97% 13
2014
Q1
$31.5M Sell
413,815
-3,206
-0.8% -$234K 0.99% 13
2013
Q4
$30M Buy
417,021
+9,308
+2% +$647K 0.97% 14
2013
Q3
$28M Buy
407,713
+9,959
+3% +$659K 0.99% 14
2013
Q2
$25.2M Buy
+397,754
New +$25.9M 0.94% 17

Other funds holding NVS

Truist Financial's NVS Position: Q1 2026 in Review

Truist Financial increased its Novartis (NVS) stake by 6.1% in Q1 2026, buying an estimated $8.36M and bringing the position to 941,818 shares worth $144M. The position accounts for 0.19% of the portfolio, ranked #103.

Truist Financial first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Truist Financial held 941,818 shares of Novartis worth $144M as of Q1 2026.
  • Truist Financial bought 54,522 Novartis shares in Q1 2026, an estimated $8.36M.
  • Novartis made up 0.19% of Truist Financial's portfolio in Q1 2026, its #103 holding.
  • Truist Financial first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.